晶泰科技(02228.HK) 宣布与新加坡国立癌症中心(NCCS)及杜克-新加坡国立大学医学院(Duke-NUS)开展AI新药发现合作,拟运用其AI和自动化实验驱动的多肽研发设计平台,针对NCCS选定的肾透明细胞癌全新靶点,发现及设计临床候选药物,并与合作方共享后续商业化成果。
晶泰科技首席创新官赖力鹏表示,公司的先进AI多肽研发算法已积累丰富成功经验,相信与NCCS及Duke-NUS团队基础和临床研究成果结合,可望为肾透明细胞癌的全新靶点研发具有巨大潜力的创新药物。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-30 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.